<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The impact of <z:chebi fb="0" ids="5959">irbesartan</z:chebi> treatment on biomarkers of low-grade <z:mp ids='MP_0001845'>inflammation</z:mp>, <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e>, growth factors, and advanced glycation end products (AGEs) during the <z:chebi fb="0" ids="5959">Irbesartan</z:chebi> in Patients with Type 2 <z:mp ids='MP_0002055'>Diabetes</z:mp> and <z:mp ids='MP_0002959'>Microalbuminuria</z:mp> (IRMA 2) study was evaluated </plain></SENT>
<SENT sid="1" pm="."><plain>IRMA 2 was a 2-year multicenter, randomized, double-blind trial in patients comparing <z:chebi fb="0" ids="5959">irbesartan</z:chebi> (150 or 300 mg once daily) versus placebo </plain></SENT>
<SENT sid="2" pm="."><plain>The primary end point was <z:hpo ids='HP_0003674'>onset</z:hpo> of overt <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>A subgroup (n = 269, 68%) was analyzed for biomarkers at baseline and after 1 and 2 years </plain></SENT>
<SENT sid="4" pm="."><plain>High-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6, fibrinogen, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules, transforming growth factor-beta, and AGE <z:chebi fb="7" ids="16670">peptides</z:chebi> were assessed </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="5959">Irbesartan</z:chebi> treatment yielded significant changes in hs-CRP (based on generalized estimating equation regression coefficient) with a 5.4% decrease per year versus a 10% increase per year in the placebo group (P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Fibrinogen decreased 0.059 g/l per year from baseline versus placebo's 0.059 g/l increase per year (P = 0.027) </plain></SENT>
<SENT sid="7" pm="."><plain>IL-6 showed a 1.8% increase per year compared with placebo's 6.5% increase per year (P = 0.005) </plain></SENT>
<SENT sid="8" pm="."><plain>Changes in IL-6 were associated with changes in albumin excretion (P = 0.04) </plain></SENT>
<SENT sid="9" pm="."><plain>There was no treatment effect on the other biomarkers </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="5959">Irbesartan</z:chebi> (300 mg once daily) reduces low-grade <z:mp ids='MP_0001845'>inflammation</z:mp> in this high-risk population, and this may reduce the risk of micro- and macrovascular disease </plain></SENT>
</text></document>